GlassScriptPhysician profile
Candace Kuzma
NPI 1477010650
$7,838.99
in general payments reported to CMS, 2019-2025
34 companies · $3,178 in 2025
The $3,178 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,053 · 2024: $3,608 · 2025: $3,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,838.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,126.04 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $880.25 | 2023-2025 | |
| Amgen INC. | $568.00 | 2023-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $499.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $444.19 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $441.19 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $380.40 | 2023-2025 | |
| Exact Sciences Corporation | $355.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $334.44 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.41 | 2023-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $147.61 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $98.38 | 2024-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.29 | 2023-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $95.62 | 2025 | Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.64 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $65.55 | 2023-2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $61.09 | 2023-2024 | Quviviq |
| Lucid Diagnostics INC. | $51.95 | 2024-2025 | |
| Medtronic, INC. | $47.85 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Lundbeck LLC | $38.38 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $37.79 | 2024-2025 | Injectafer |
| Amneal Pharmaceuticals LLC | $37.04 | 2024 | Unithroid |
| Sanofi-Aventis U.S. LLC | $36.31 | 2024-2025 | |
| Abbott Laboratories | $35.67 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $34.45 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $30.09 | 2024-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $27.52 | 2024 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $25.57 | 2025 | |
| Noven Therapeutics, LLC | $24.04 | 2024 | Xelstrym |
| Eisai INC. | $22.55 | 2024 | |
| Inspire Medical Systems, INC. | $21.87 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $14.37 | 2024 | Contrave |
| Xeris Pharmaceuticals, INC. | $14.04 | 2024 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Kuzma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.